Optimal impulsive control in RNA interference mediated by exogenous dsRNA with physiological delays.

Therapeutic agents acting on RNA, including RNA modification, RNA editing and RNA interference (RNAi), play a vital role in gene function study, signaling pathway, drug discovery, disease treatment, vaccine development and so on. Therein, RNAi as an emerging gene therapy has been widely applied in many cancer studies by silencing oncogenes or specific mRNA in malignant tumor cells. Mechanism and efficiency of RNAi are the key issues of RNAi technology. RNA silencing involves dynamic modeling, analyses and optimal control of RNAi gene system. Physiological delay and Hill response describing off-target are considerable elements involving RNAi efficiency. In this paper, we first formulate a four-dimensional RNAi model with time delays and Hill functions, and then investigate the complex dynamic behaviors including the number, existence and stability of internal equilibria and Hopf bifurcations of single delay and two delays. Furthermore, based on the specific mRNA degradation adopted in impulsive patterns, we build an optimal problem by adding exogenous dsRNA at alterable time points in variable dosages in a treatment session. By the method of gradient formula, we can find the optimal impulsive time and proportion of dsRNA. Finally, simulation indicates that (1) physiological lags not only raise the oscillations of mRNA but also cut down the levels of cost; (2) smaller delays and larger rates of siRNA–mRNA complex formation and dsRNA synthesis imply the rapid composition of RISC and fast synthesis of dsRNA leading to more desirable therapeutic schedule, which affords evidence for gene regulation and RNAi; (3) a larger half-saturation coefficient characterizes a unique and stable higher targeted mRNA, whereas a smaller half-saturation coefficient generates bistability in which the higher and lower targeted mRNAs simultaneously emerge; and (4) the bistability will provide a good guidance to control, suppress and degrade targeted mRNA. [ABSTRACT FROM AUTHOR]